Cannabis Use Disorder Market Surge Driven by Expanding Treatment Innovations

The Cannabis Use Disorder Market is experiencing significant transformation fueled by advanced therapeutic developments and heightened awareness of cannabis-related health issues. This dynamic industry witnesses accelerating growth due to increasing investments in innovative treatment methods addressing cannabis dependence and associated behavioral disorders. Market insights point toward expanding opportunities amid evolving market dynamics and regulatory reinforcements.

Market size and Overview

The Global Cannabis Use Disorder Market size is estimated to be valued at USD 1.80 billion in 2025 and is expected to reach USD 3.40 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.5% from 2025 to 2032.

The robust Cannabis Use Disorder Market forecast underscores growing market revenue driven by increased healthcare expenditure and rising demand for effective cannabis dependency treatments globally. Innovating clinical approaches and approval of novel pharmacological products bolster the market scope, reflecting a positive industry size expansion and encouraging business growth.

Key Takeaways

- Dominating Region: North America continues to dominate in 2025 owing to stringent government policies and advanced healthcare infrastructure supporting treatment adoption, as highlighted by recent FDA approvals targeting cannabis use disorder therapies.

- Fastest Growing Region: Asia Pacific demonstrates the fastest growth, propelled by increasing healthcare awareness and rising cannabis consumption rates in countries like India and China.

- By Treatment Type Segment:
- Dominant Sub-Segment: Pharmacotherapy remains the leading treatment approach, with companies introducing novel drug formulations.
- Fastest Growing Sub-Segment: Behavioral therapies are witnessing rapid adoption due to integration with digital health platforms, exemplified by emerging teletherapy services launched in 2024.

- By Therapeutic Application Segment:
- Dominant Sub-Segment: Withdrawal management accounts for the most significant share with continuous development of withdrawal intervention programs.
- Fastest Growing Sub-Segment: Relapse prevention techniques are expanding quickly, enhanced by real-world patient data supporting efficacy.

- By End-User Segment:
- Dominant Sub-Segment: Hospitals and specialty clinics have the largest uptake, supported by increased treatment capacity.
- Fastest Growing Sub-Segment: Outpatient centers are growing rapidly due to convenience and cost-effectiveness for patients.

Market Key Trends

A principal market trend shaping the Cannabis Use Disorder Market is the integration of digital therapeutics with conventional treatment pathways. In 2024, several market companies introduced app-based cognitive behavioral therapy (CBT) solutions that complement pharmacological options, improving patient adherence and outcomes. For example, a pilot study published in 2025 demonstrated a 30% reduction in relapse rates among patients supplemented with digital therapies. This market driver enhances market growth strategies by combining technology and medicine, addressing market challenges related to treatment accessibility and patient engagement. Regulatory bodies are increasingly recognizing digital interventions, adding impetus to market opportunities and expanding the market forecast projections positively.

Key Players

Key players operating within the Cannabis Use Disorder Market include Aelis Farma, Indivior, Pfizer, Corbus Pharmaceuticals, and Zynerba Pharmaceuticals, among others. Strategies adopted by these market companies include strategic partnerships to accelerate R&D and expand treatment portfolios. For instance, in 2024, Pfizer collaborated with a biotech firm to develop targeted cannabinoid receptor modulators, bolstering their pipeline. Indivior has expanded its presence through acquisition of niche startups, enhancing market share and revenue streams. Additionally, market players emphasize innovation in clinical trials and patient-centric treatment models, reinforcing their industry size and solidifying sustained business growth.

FAQs

1. Who are the dominant players in the Cannabis Use Disorder Market?
Leading companies include Aelis Farma, Indivior, Pfizer, Corbus Pharmaceuticals, and Zynerba Pharmaceuticals, who are driving innovation through pharmacotherapy and behavioral treatment solutions.

2. What will be the size of the Cannabis Use Disorder Market in the coming years?
The market size is projected to grow from USD 1.80 billion in 2025 to approximately USD 3.40 billion by 2032, with a CAGR of 9.5%.

3. Which end-user industry segment presents the largest growth opportunity?
Hospitals and specialty clinics hold the largest industry share, but outpatient centers are rapidly growing due to accessibility and cost benefits.

4. How will market development trends evolve over the next five years?
Market trends will likely focus on integrating digital therapeutics with pharmacological treatments, enhancing patient engagement, and improving treatment outcomes.

5. What is the nature of the competitive landscape and challenges in the Cannabis Use Disorder Market?
The competitive landscape is marked by innovation-driven collaborations and expansions. Challenges include regulatory complexities and ensuring accessibility for diverse patient populations.

6. What go-to-market strategies are commonly adopted in the Cannabis Use Disorder Market?
Key players employ strategic partnerships, acquisition of specialized startups, and investment in clinical trials, focusing on expanding their treatment portfolio and addressing unmet market needs.

Get this Report in Japanese Language: 大麻使用障害市場

Get this Report in Korean Language:   대마사용장애시장

Author Bio:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163 )